Investments
91Portfolio Exits
14Funds
4Latest Section 32 News
Jan 26, 2022
Section 32 Expands Investment Team with the Addition of Carlos Solórzano, Ph.D. SAN DIEGO, January 25, 2022-- Section 32, a venture capital fund investing at the frontiers of technology and healthcare, announced today the addition of Carlos Solórzano, Ph.D., as Senior Principal to support the continued growth of its investing team. Carlos, an accomplished scientist, equity research analyst and life sciences venture investor, will be based at Section 32's location in Los Altos. "It's a pleasure to welcome Carlos to our team," said Section 32 Managing Partner Andy Harrison. "Carlos' broad experiences evaluating healthcare investment opportunities through the lenses of investment banking, venture and corporate development complement our growing investment team. We look forward to Carlos' contributions to our efforts as we build our portfolio of technology and healthcare companies." As a Senior Principal at Section 32, Carlos focuses on the firm's investment sourcing, diligence, and deal execution efforts. Prior to Section 32, Carlos served as a Senior Associate for Pivotal bioVenture Partners, a life sciences venture fund, where he led and participated in diligence, term sheet negotiation, deal syndication and other deal processes for its life sciences portfolio. Previously, Carlos was an Associate Director, Corporate Strategy and Business Development for Ultragenyx Pharmaceutical, where he worked on competitive intelligence, as well as portfolio development, commercial partnerships and strategy. Carlos also worked as an equity research associate at Deutsche Bank and Oppenheimer & Co. covering small-, mid- and large-cap biotech companies. Carlos earned his Ph.D. in Pharmacology and Toxicology from UC Irvine and was an NIH postdoctoral scholar, Neuroscience, at UC San Francisco, where he investigated the neurobiology of pain and itch. He received a B.S. in Chemical Engineering from Cal Poly Pomona. About Section 32 Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com
Section 32 Investments
91 Investments
Section 32 has made 91 investments. Their latest investment was in Character Biosciences as part of their Series A on May 5, 2022.
Section 32 Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
5/17/2022 | Series A | Character Biosciences | $18M | Yes | 2 | |
5/12/2022 | Series B | Legacy | $25M | No | 2 | |
5/10/2022 | Series B | MOMA Therapeutics | $150M | Yes | 7 | |
5/9/2022 | Series B | |||||
4/25/2022 | Series C |
Date | 5/17/2022 | 5/12/2022 | 5/10/2022 | 5/9/2022 | 4/25/2022 |
|---|---|---|---|---|---|
Round | Series A | Series B | Series B | Series B | Series C |
Company | Character Biosciences | Legacy | MOMA Therapeutics | ||
Amount | $18M | $25M | $150M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 2 | 7 |
Section 32 Portfolio Exits
14 Portfolio Exits
Section 32 has 14 portfolio exits. Their latest portfolio exit was Current Health on October 12, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/12/2021 | Acquired | 3 | |||
9/24/2021 | IPO | Public | 21 | ||
9/7/2021 | Acquired | 5 | |||
Date | 10/12/2021 | 9/24/2021 | 9/7/2021 | ||
|---|---|---|---|---|---|
Exit | Acquired | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 3 | 21 | 5 |
Section 32 Fund History
4 Fund Histories
Section 32 has 4 funds, including Section 32 Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
2/21/2019 | Section 32 Fund II | Early-Stage Venture Capital | Open | $199.35M | 6 |
5/22/2017 | Section 32 Fund I | ||||
Section 32 Fund IV | |||||
Section 32 Fund III |
Closing Date | 2/21/2019 | 5/22/2017 | ||
|---|---|---|---|---|
Fund | Section 32 Fund II | Section 32 Fund I | Section 32 Fund IV | Section 32 Fund III |
Fund Type | Early-Stage Venture Capital | |||
Status | Open | |||
Amount | $199.35M | |||
Sources | 6 |
Section 32 Team
4 Team Members
Section 32 has 4 team members, including current Chief Financial Officer, Chief Operating Officer, Nina Ebert.
Name | Work History | Title | Status |
|---|---|---|---|
Nina Ebert | Trinity Ventures, Silicon Valley Bank, Health Evolution Partners, Labrador Ventures, Saints Capital, PeoplePC, Montgomery, and Goldman Sachs | Chief Financial Officer, Chief Operating Officer | Current |
Andrew Harrison | Google, Northwater Capital Management, Celtic House Venture Partners, RBC Venture Partners, and National Research Council Canada | Managing Partner | Current |
Steve Kafka | Managing Partner | Current | |
Michael Pellini | Managing Partner | Current |
Name | Nina Ebert | Andrew Harrison | Steve Kafka | Michael Pellini |
|---|---|---|---|---|
Work History | Trinity Ventures, Silicon Valley Bank, Health Evolution Partners, Labrador Ventures, Saints Capital, PeoplePC, Montgomery, and Goldman Sachs | Google, Northwater Capital Management, Celtic House Venture Partners, RBC Venture Partners, and National Research Council Canada | ||
Title | Chief Financial Officer, Chief Operating Officer | Managing Partner | Managing Partner | Managing Partner |
Status | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.